This decision, published in the French Journal Officiel (JO) on December 26, 20241, 2, allows healthcare providers to receive reimbursement for remote monitoring of gestational diabetes (GDM) in patients not treated with insulin.
This expands upon the existing reimbursement for Glooko XT for remote monitoring of people with insulin-treated diabetes, making it one of only two solutions in France with this GDM indication and further demonstrating the value of this technology in diabetes management.
GDM has a significant impact on maternal and fetal health in France:
- Prevalence: GDM affects an estimated 8.8% of pregnancies in France.3
- Health Risks: GDM increases risks of preeclampsia, cesarean delivery, and type 2 diabetes in mothers. For newborns, it can lead to macrosomia, preterm birth, and respiratory distress.4
The HAS approval is based on the recognition that Glooko XT provides a valuable complementary monitoring option for conventional medical follow-up of GDM. The specific indications for reimbursement include:
- Non insulin treated pregnant women diagnosed with GDM through a positive oral glucose tolerance test (OGTT) performed between the 24th and 28th week of amenorrhea, or with a fasting blood glucose level greater than or equal to 0.92g/L during the first trimester of pregnancy in the presence of at least one risk factor.